Olivier Donnez
Overview
Explore the profile of Olivier Donnez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1154
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Donnez J, Becker C, Taylor H, Carmona Herrera F, Donnez O, Horne A, et al.
Hum Reprod
. 2024 Apr;
39(6):1208-1221.
PMID: 38648863
Study Question: Does linzagolix administered orally once daily for up to 3 months at a dose of 75 mg alone or 200 mg in combination with add-back therapy (ABT) (1.0 ...
2.
Donnez O
Best Pract Res Clin Obstet Gynaecol
. 2023 Aug;
90:102398.
PMID: 37598564
Cesarean scar disorder (CSD) is an entity recently defined as uterine niche with at least one primary or 2 secondary symptoms. CSDs can be visualized by hysterosalpingography, transvaginal sonography, saline...
3.
Donnez J, Donnez O, Dolmans M
Fertil Steril
. 2023 Jul;
120(5):1071-1073.
PMID: 37495010
No abstract available.
4.
Delage de Luget C, Becchis E, Fernandez H, Donnez O, Quarello E
J Gynecol Obstet Hum Reprod
. 2021 Dec;
51(3):102299.
PMID: 34958983
Uterine niche is a potential significant consequence of Caesarean section and is diagnosed by ultrasound. The timing of Caesarean section (during pre, early or advanced labour), location of the incision...
5.
Donnez J, Donnez O, Tourniaire J, Brethous M, Bestel E, Garner E, et al.
J Clin Med
. 2021 Dec;
10(24).
PMID: 34945090
(1) Background: The aim of the present pilot study was to study the effect of a new oral gonadotropin-releasing hormone antagonist on adenomyosis. (2) Methods: Eight premenopausal women, aged between...
6.
Donnez J, Donnez O, Brethous M, Bestel E, Garner E, Charpentier S, et al.
Reprod Biomed Online
. 2021 Nov;
44(1):200-203.
PMID: 34799277
Research Question: Does a once-daily regimen of linzagolix, a new oral gonadotrophin-releasing hormone (GnRH) antagonist, given at a fully suppressive dose (200 mg) for 12 weeks, followed by a partially...
7.
Donnez O
J Clin Med
. 2021 Nov;
10(21).
PMID: 34768704
Deep endometriosis infiltrating the rectum remains a challenging situation to manage, and it is even more important when ureters and pelvic nerves are also infiltrated. Removal of deep rectovaginal endometriosis...
8.
9.
Donnez O, Donnez J
Best Pract Res Clin Obstet Gynaecol
. 2020 Jul;
71:100-113.
PMID: 32653335
Deep endometriosis (DE) is considered to be one of the most challenging conditions to manage, especially when it invades surrounding organs like the rectum. Surgical excision of deep rectovaginal endometriosis...
10.
Donnez O, Donnez J
Fertil Steril
. 2020 Jun;
114(3):640-645.
PMID: 32507315
Objective: To compare the efficacy of a selective progesterone receptor modulator, ulipristal acetate, and a gonadotropin-releasing hormone antagonist, linzagolix, in a case of severe uterine adenomyosis. Design: Case report. Setting:...